Condition: Intestinal Malabsorption · Sponsor: Elgan Pharma Ltd.
To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants\<3rd percentile\* born at 26-32 weeks GA.
This description comes directly from the study's public registry record.
Miki Olshansky · 972-4-6098626 · CA@elganpharma.com
Always discuss trial participation with your own doctor first.
| Laniado Hospital | Netanya, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05904626